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2 
Abstract 13 
Sequencing-based studies have identified novel risk genes for severe epilepsies and revealed an 14 
excess of rare deleterious variation in less severe forms of epilepsy. To identify the shared and 15 
distinct ultra-rare genetic risk factors for different types of epilepsies, we performed a whole-16 
exome sequencing (WES) analysis of 9,170 epilepsy-affected individuals and 8,364 controls of 17 
European ancestry. We focused on three phenotypic groups; severe developmental and epileptic 18 
encephalopathies (DEE), genetic generalized epilepsy (GGE), and non-acquired focal epilepsy 19 
(NAFE). We observed that compared to controls, individuals with any type of epilepsy carried an 20 
excess of ultra-rare, deleterious variants in constrained genes and in genes previously associated 21 
with epilepsy, with the strongest enrichment seen in DEE and the least in NAFE. Moreover, we 22 
found that inhibitory GABAA receptor genes were enriched for missense variants across all three 23 
classes of epilepsy, while no enrichment was seen in excitatory receptor genes. The larger gene 24 
groups for the GABAergic pathway or cation channels also showed a significant mutational 25 
burden in DEE and GGE. Although no single gene surpassed exome-wide significance among 26 
individuals with GGE or NAFE, highly constrained genes and genes encoding ion channels were 27 
among the top associations, including CACNA1G, EEF1A2, and GABRG2 for GGE and LGI1, 28 
TRIM3, and GABRG2 for NAFE. Our study confirms a convergence in the genetics of severe and 29 
less severe epilepsies associated with ultra-rare coding variation and highlights a ubiquitous role 30 
for GABAergic inhibition in epilepsy etiology in the largest epilepsy WES study to date.  31 
3 
Introduction 32 
Epilepsy is a group of disorders characterized by repeated seizures due to excessive electrical 33 
activity in the brain and is one of the most common neurological conditions affecting every 5-7 of 34 
1000 individuals worldwide1; 2. Human genetics research has established that a genetic basis 35 
underlies the susceptibility to epilepsy for a majority of the cases3-6. However, the multifactorial 36 
condition of epilepsy that subsumes a variety of epilepsy types, seizures, levels of severity, and 37 
comorbidity has made it a core challenge to disentangle the genetic architecture for different types 38 
of epilepsy and to determine the specific genetic risks for individual patients. 39 
 In recent years, our understanding of the genetic risk factors of epilepsy has substantially 40 
expanded thanks to the rapid advancement in sequencing technology. Currently, gene 41 
identification from sequencing-based studies has been primarily limited to rare, monogenic forms 42 
of epilepsy, particularly for a group of severe epilepsy syndromes, known as the developmental 43 
and epileptic encephalopathies (DEE)7-11. DEE typically begin early in life and are characterized 44 
by intractable seizures and profound to mild developmental impairment. It was found that 1 in 45 
2,000 infants develop severe epilepsies with onset under 18 months12. For these severe 46 
epilepsies, dozens of genes with de novo pathogenic variants have been identified and the 47 
number continues to grow. The other major epilepsy types broadly encompass genetic 48 
generalized epilepsy (GGE) and non-acquired focal epilepsy (NAFE), the former characterized 49 
by seizures involving both hemispheres of the brain, the latter a localized cortical region. The 50 
incidence of these groups is not well-established, but they are recognized as the more common, 51 
less severe forms of epilepsy, and epidemiological studies have estimated generalized and focal 52 
epilepsies each account for 20-40% of incident epilepsies13-16. Similar to DEE, there are several 53 
specific electroclinical syndromes within the class of GGE and NAFE, but the genetic etiology is 54 
more complex. Genetic investigations into GGE or NAFE thus far support both a role for a 55 
oligogenic or polygenic component17-20 as well as some evidence for monogenic causes for a 56 
minority of patients5. Despite a significant heritability consistently demonstrated from twin, family, 57 
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and genome-wide association studies (GWAS)4; 19-22, single gene discovery has remained scarce 58 
for GGE and NAFE. Most genes identified to date come from monogenic families of focal 59 
epilepsies, while attempts to identify risk genes for GGE have been largely unsuccessful23-25. For 60 
most of the GGE and NAFE patients with a non-familial onset, the specific pathogenic variants 61 
are not yet known, and gene findings from small-scale studies have often not been reproducible26-62 
28. 63 
Two recent whole-exome sequencing (WES) case-control studies leveraged hundreds of 64 
familial cases and provided clear evidence of specific gene groups linked to the risk of GGE and 65 
NAFE24; 25. Specifically, the authors showed that ultra-rare genetic variation in genes associated 66 
with DEE was enriched in GGE and NAFE, and that enrichment of missense variants in all genes 67 
encoding GABAA receptors was observed for the first time in GGE. These findings highlight that 68 
genes commonly implicated in epilepsy can span a wider range of epilepsy phenotypes than 69 
previously postulated. Studying rare genetic variation involving severe to milder electroclinical 70 
syndromes of epilepsy can help to better understand the extent of phenotypic pleiotropy and 71 
variable expressivity that may inform treatment strategies. On the other hand, the extensive 72 
phenotypic and genetic heterogeneity of epilepsy, especially for GGE and NAFE, underscores 73 
the need to enlarge the scale of such studies and beyond familial cases. 74 
Here, we evaluate a WES case-control study of epilepsy from the Epi25 collaborative—75 
an ongoing global effort to collect an unprecedented number of patient cohorts for primarily the 76 
three major classes of non-lesional epilepsies: DEE, GGE, and NAFE29. We aimed to pinpoint the 77 
distinct and overlapping genetic risk of ultra-rare coding variants across these different phenotypic 78 
groups by evaluating the burden at the individual gene level and in candidate gene sets to 79 
understand the role of rare genetic variation in epilepsy and identify specific epilepsy risk genes.  80 
5 
Subjects and Methods 81 
Study design and participants 82 
We collected DNA and detailed phenotyping data on individuals with epilepsy from 37 sites in 83 
Europe, North America, Australasia and Asia (Supplemental Subjects and Methods; Table S1).  84 
Here we analyzed subjects with genetic generalized epilepsy (GGE, also known as idiopathic 85 
generalized epilepsy; N=4,453), non-acquired focal epilepsy (NAFE; N=5,331) and 86 
developmental and epileptic encephalopathies (DEE; N=1,476); and a small number of other 87 
epilepsies were also included in the initiative (Table S1).   88 
Control samples were aggregated from local collections at the Broad Institute (Cambridge, 89 
MA, USA) or obtained from dbGaP, consisting of 17,669 individuals of primarily European 90 
ancestry who were not ascertained for neurological or neuropsychiatric conditions (Table S2; 91 
Supplemental Subjects and Methods). 92 
Phenotyping procedures   93 
Epilepsies were diagnosed on clinical grounds based on criteria given in the next paragraph (see 94 
below for GGE, NAFE and DEE, respectively) by experienced epileptologists and consistent with 95 
International League Against Epilepsy (ILAE) classification at the time of diagnosis and 96 
recruitment. De-identified (non-PHI [protected health information]) phenotyping data were entered 97 
into the Epi25 Data repository hosted at the Luxembourg Centre for Systems Biomedicine via 98 
detailed on-line case record forms based on the RedCAP platform. Where subjects were part of 99 
previous coordinated efforts with phenotyping on databases (e.g., the Epilepsy 100 
Phenome/Genome Project30 and the EpiPGX project (www.epipgx.eu)), deidentified data were 101 
accessed and transferred to the new platform. Phenotyping data underwent review for uniformity 102 
among sites and quality control by automated data checking, followed by manual review if 103 
required. Where doubt remained about eligibility, cases were reviewed by the phenotyping 104 
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committee and sometimes further data was requested from the source site before a decision was 105 
made. 106 
Case Definitions 107 
GGE required a convincing history of generalized seizure types (generalized tonic-clonic seizures, 108 
absence, or myoclonus) and generalized epileptiform discharges on EEG. We excluded cases 109 
with evidence of focal seizures, or with moderate to severe intellectual disability and those with 110 
an epileptogenic lesion on neuroimaging (although neuroimaging was not obligatory). If a 111 
diagnostic source EEG was not available, then only cases with an archetypal clinical history as 112 
judged by the phenotyping committee (e.g., morning myoclonus and generalized tonic-clonic 113 
seizures for a diagnosis of Juvenile Myoclonic Epilepsy) were accepted. 114 
Diagnosis of NAFE required a convincing history of focal seizures, an EEG with focal 115 
epileptiform or normal findings (since routine EEGs are often normal in focal epilepsy), and 116 
neuroimaging showing no epileptogenic lesion except hippocampal sclerosis (MRI was preferred 117 
but CT was accepted). Exclusion criteria were a history of generalized onset seizures or moderate 118 
to severe intellectual disability. 119 
The DEE group comprised subjects with severe refractory epilepsy of unknown etiology 120 
with developmental plateau or regression, no epileptogenic lesion on MRI, and with epileptiform 121 
features on EEG. As this is the group with the largest number of gene discoveries to date, we 122 
encouraged inclusion of those with non-explanatory epilepsy gene panel results, but we did not 123 
exclude those without prior testing (Table S7). 124 
Informed Consent 125 
Adult subjects, or in the case of children, their legal guardians, provided signed informed consent 126 
at the participating centers according to local national ethical requirements. Samples had been 127 
collected over a 20-year period in some centers, so the consent forms reflected standards at the 128 
time of collection. Samples were only accepted if the consent did not exclude data sharing. For 129 
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samples collected after January 25, 2015, consent forms required specific language according to 130 
the NIH Genomic Data Sharing policy (http://gds.nih.gov/03policy2.html). 131 
 132 
Whole exome sequencing data generation 133 
All samples were sequenced at the Broad Institute of Harvard and MIT on the Illumina HiSeq X 134 
platform, with the use of 151 bp paired-end reads. Exome capture was performed with Illumina 135 
Nextera® Rapid Capture Exomes or TruSeq Rapid Exome enrichment kit (target size 38 Mb), 136 
except for three control cohorts (MIGen ATVB, MIGen Ottawa, and Swedish SCZ controls) for 137 
which the Agilent SureSelect Human All Exon Kit was used (target size 28.6 Mb – 33 Mb). 138 
Sequence data in the form of BAM files were generated using the Picard data-processing pipeline 139 
and contained well-calibrated reads aligned to the GRCh37 human genome reference. Samples 140 
across projects were then jointly called via the Genome Analysis Toolkit (GATK) best practice 141 
pipeline31 for data harmonization and variant discovery. This pipeline detected single nucleotide 142 
(SNV) and small insertion/deletion (indel) variants from exome sequence data. 143 
 144 
Quality control  145 
Variants were pre-filtered to keep only those passing the GATK VQSR (Variant Quality Score 146 
Recalibration) metric and those lying outside of low complexity regions32. Genotypes with GQ < 147 
20 and heterozygous genotype calls with allele balance > 0.8 or < 0.2 were set to missing. To 148 
control for capture platform difference, we retained variants that resided in GENCODE coding 149 
regions where 80% of Agilent and Illumina-sequenced samples show at least 10x coverage. This 150 
resulted in the removal of ~50% of the called sites (23% of the total coding variants and 97% of 151 
the total non-coding variants) but effectively reduced the call rate difference between cases and 152 
controls (Figure S1). To further identify potential false positive sites due to technical variation, we 153 
performed single variant association tests (for variants with a minor allele frequency MAF > 0.001) 154 
among the controls, treating one platform as the pseudo-case group with adjustment for sex and 155 
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the first ten principal components (PCs), and removed variants significantly associated with 156 
capture labels (p-value < 0.05). We also excluded variants with a call rate < 0.98, case-control 157 
call rate difference > 0.005, or Hardy-Weinberg Equilibrium (HWE) test p-value < 1×10-6 based 158 
on the combined case and control cohort. 159 
Samples were excluded if they had a low average call rate (< 0.98), low mean sequence 160 
depth (< 30; Figure S2), low mean genotype quality (< 85), high freemix contamination estimate 161 
(> 0.04), or high percent chimeric reads (> 1.4%). We performed a series of principal component 162 
analyses (PCAs) to identify ancestral backgrounds and control for population stratification, 163 
keeping only individuals of European (EUR) ancestry classified by Random Forest with 1000 164 
Genomes data (Figure S3). Within the EUR population, we removed controls not well-matched 165 
with cases based on the top two PCs, and individuals with an excessive or a low count of 166 
synonymous singletons—a number that increases with the North-to-South axis (Figure S4). We 167 
also removed one sample from each pair of related individuals (proportion identity-by-descent > 168 
0.2) and those whose genetically imputed sex was ambiguous or did not match with self-reported 169 
sex. Outliers (>4SD from the mean) of transition/transversion ratio, heterozygous/homozygous 170 
ratio, or insertion/deletion ratio within each cohort were further discarded (Figures S5-7). At the 171 
phenotype level, we removed individuals with epilepsy phenotype to-be-determined or marked as 172 
“excluded” from further review.    173 
The number of variant and sample dropouts at each step are detailed in Tables S3 and 174 
S4.  175 
 176 
Variant annotation 177 
Annotation of variants was performed with Ensembl’s Variant Effect Predictor (VEP)33 for human 178 
genome assemble GRCh37. Based on the most severe consequence, we defined four mutually 179 
exclusive functional classes of variants using relevant terms and SnpEff34 impact (Table S5): 180 
protein-truncating variant (PTV), damaging missense (predicted by PolyPhen-2 and SIFT), 181 
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other/benign missense (predicted by PolyPhen-2 and SIFT), and synonymous. To further 182 
discriminate likely deleterious missense variants from benign missense variants, we applied an in 183 
silico missense deleteriousness predictor (“Missense badness, PolyPhen-2, and regional 184 
Constraint”, or MPC score)35 that leverages regional constraint information to annotate a subset 185 
of missense variants that are highly deleterious (MPC ≥ 2). The MPC ≥ 2 group accounts for a 186 
small proportion of the total damaging and benign missense variants annotated by PolyPhen-2 187 
and SIFT. Because many of our control samples were obtained from external datasets used in 188 
the Exome Aggregation Consortium (ExAC)36 (Table S2), we used the DiscovEHR cohort—an 189 
external population allele frequency reference cohort that contains 50,726 whole-exome 190 
sequences from a largely European and non-diseased adult population37—to annotate if a variant 191 
is absent in the general population (Figure S8). 192 
 193 
Gene-set burden analysis 194 
To estimate the excess of rare, deleterious protein-coding variants in individuals with epilepsy, 195 
we conducted burden tests across the entire exome, for biologically relevant gene sets and at the 196 
individual gene level. We focused on two definitions of “ultra-rare” genetic variation (URV) for the 197 
primary analyses—variants not seen in the DiscovEHR database and observed only once among 198 
the combined case and control test cohort (allele count AC=1) or absent in DiscovEHR and 199 
observed no more than three times in the test cohort (allele count AC≤3)—where the strongest 200 
burden of deleterious pathogenic variants have been observed previously24; 38 and in our study 201 
compared to less stringent allele frequency thresholds (Figure S9 & S10). We performed these 202 
case-control comparisons separately for each of the three primary epilepsy disorders (DEE, GGE, 203 
NAFE) and again for all epilepsy-affected individuals combined. 204 
 Gene-set burden tests were implemented using logistic regression to examine the 205 
enrichment of URVs in individuals with epilepsy versus controls. We performed the test by 206 
regressing case-control status on certain classes of URVs aggregated across a target gene set 207 
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in an individual, adjusting for sex, the top ten PCs, and exome-wide variant count. This analysis 208 
tested the burden of URVs separately for five functional coding annotations: synonymous, benign 209 
missense predicted by PolyPhen-2 and SIFT, damaging missense predicted by PolyPhen-2 and 210 
SIFT, protein-truncating variants, and missense with MPC≥2 (Table S5). To help determine 211 
whether our burden model was well calibrated, we used synonymous substitutions as a negative 212 
control, where significant burden effects would more likely indicate insufficient control of 213 
population stratification or exome capture differences. The inclusion of overall variant count as a 214 
covariate—which tracks with ancestry—made our test conservative but allows for better control 215 
of residual population stratification not captured by PCs, and effectively reduces inflation of 216 
signals in synonymous variants (Figure S11). We collected and tested eleven different gene sets, 217 
including constrained genes that are intolerant to loss-of-function mutations (pLI > 0.9 and pLI > 218 
0.99539) or missense variation (mis-Z > 3.0939), brain-enriched genes that express more than 2-219 
fold in brain tissues compared to other tissues based on Genotype-Tissue Expression Consortia 220 
(GTEx) data40, and genes reported to be associated with epilepsy in a dominant fashion10; 24 or 221 
epilepsy-related mechanisms25 (Table S6). Unlike the gene-based burden tests, because most 222 
of the gene-set tests were not independent, we used a false discovery rate (FDR) correction for 223 
multiple testing that accounted for the number of functional categories (5), gene sets (11) and 224 
epilepsy phenotypes (4), totaling 220 tests, and defined a significant enrichment at FDR < 0.05.  225 
 226 
Gene-based collapsing analysis 227 
 For gene-based tests, we restricted to deleterious URVs annotated as either PTV, 228 
missense with MPC≥2, or in-frame insertion/deletion. For each gene, individuals who had at least 229 
one copy of these deleterious variants were counted as a carrier, and we used a two-tailed 230 
Fisher’s Exact test (FET) to assess if the proportion of carriers among epilepsy subgroup cases 231 
was significantly higher than controls. Instead of assuming a uniform distribution for p-values 232 
under the null, we generated empirical p-values by permuting case-control labels 500 times, 233 
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ordering the FET p-values of all genes for each permutation, and taking the average across all 234 
permutations to form a rank-ordered estimate of the expected p-value distribution. This was done 235 
by modifying functions in the “QQperm” R package41. To avoid potential false discoveries, we 236 
defined a stringent exome-wide significance as p-value < 6.8e-07, using Bonferroni correction to 237 
account for 18,509 consensus coding sequence genes tested and the four individual case-control 238 
comparisons.  239 
Considering that recessive pathogenic variants were implicated in a number of epilepsy-240 
associated genes, mostly identified from individuals with a DEE phenotype8, we conducted a 241 
secondary gene-based Fisher’s exact test using a recessive model, comparing the proportion of 242 
carriers that are homozygous for the minor allele between cases and controls. The recessive 243 
model was assessed for PTVs, missense (MPC≥2) variants, and in-frame indels separately. For 244 
this analysis, we did not restrict to non-DiscovEHR variants and relaxed the allele frequency up 245 
to MAF < 0.01 to account for the sparse occurrences. 246 
Additionally, to evaluate the contribution of low frequency deleterious variants to epilepsy 247 
risk, we explored the gene burden of all protein-truncating and damaging missense variants for 248 
those with a MAF < 0.01 using SKAT42, including sex and the top ten PCs as covariates in the 249 
analysis. We performed the tests with the default weighting scheme (dbeta(1,25)). 250 
 251 
Single variant association 252 
Associations of common and low-frequency variants (MAF > 0.001) with epilepsy were estimated 253 
using logistic regression by Firth’s method, correcting for sex and the first ten PCs. 254 
 255 
Quality control, annotation, and analysis were largely performed using Hail43, an open-source 256 
software for scalable genomic data analysis, in conjunction with R (version 3.4.2).  257 
12 
Results 258 
Whole exome sequencing, quality control, and sample overview 259 
We performed WES on an initial dataset of over 30,000 epilepsy affected and control individuals. 260 
After stringent quality control (QC), we identified a total of 9,170 individuals with epilepsy and 261 
8,436 controls without reported neurological or neuropsychiatric-related conditions, all of whom 262 
were unrelated individuals of European descent. Among the individuals with epilepsy, 1,021 were 263 
diagnosed with DEE, 3,108 with GGE, 3,597 with NAFE, and 1,444 with other epilepsy syndromes 264 
(lesional focal epilepsy, febrile seizures, and others). Cases and controls were carefully matched 265 
on genetic ancestry to eliminate the possibility of false positive findings induced by population 266 
stratification or effects of variable minor allele frequency resolution that occur when studying 267 
individuals from differing ancestries. Due to the lack of cosmopolitan controls from non-European 268 
populations, cases identified from PCA with a non-European ancestry were removed. 269 
Furthermore, to ensure the distribution of rare variants was balanced between cases and 270 
controls44, we removed a subset of case and control-only cohorts (from Sweden, Finland, Cyprus, 271 
and Turkey) where the mean synonymous singleton count that significantly deviated from the 272 
overall average being the consequence of incomplete ancestry matching (Figure S4). We called 273 
a total of 1,844,644 sites in 18,509 genes in the final dataset, comprising 1,811,325 SNVs and 274 
33,319 indels, 48.5% of which were absent in the DiscovEHR database37. Among the non-275 
DiscovEHR sites, 85% were singletons (defined as only one instance of that variant), and 99% 276 
had a minor allele count (AC) not more than three (equivalent to MAF ≤0.01%; Figure S8); the 277 
missense with MPC≥2 annotation accounted for 2.0% of the total missense variants (5.5% of the 278 
damaging and 1.0% of the benign missense variants predicted by PolyPhen-2 and SIFT). In our 279 
primary burden analyses, we focused on the “ultra-rare” non-DiscovEHR variants (URVs) that are 280 
unique to the 17,606 individuals under study and are seen either only once (AC=1) or no more 281 
than three times (AC≤3) in our dataset. These URVs were shown to confer the largest risk of 282 
epilepsy compared to singletons observed in DiscovEHR, doubletons, or beyond (Figure S9 & 283 
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S10). As previously described, epilepsy enrichment signals diminished with an increase in allele 284 
frequency24. 285 
 286 
Enrichment of ultra-rare deleterious variants in constrained genes in DEE and GGE 287 
We first tested the burden of singleton URVs for each epilepsy subgroup, as well as for all 288 
epilepsy-affected individuals combined, versus controls among gene sets collected based on 289 
current understanding and hypothesis of epilepsy causation. These included genes under 290 
evolutionary constraint, genes highly expressed in the brain, genes previously associated with 291 
epilepsy, GABAA receptor subunit-encoding genes, genes delineating GABAergic pathways, 292 
genes encoding excitatory neuronal receptors, and cation channel-encoding genes. (Table S6). 293 
To evaluate the burden in constrained genes, we defined “loss-of-function (LoF) intolerant” genes 294 
with either a pLI score36 > 0.9 (3,488 genes) or separately a pLI score > 0.995 (1,583 genes) and 295 
those as “missense-constrained” for genes with a missense Z-score > 3.09 (1,730 genes)39. 296 
Genes marked by these specific cut-offs have been shown to be extremely intolerant to loss-of-297 
function or missense variation and thus help to identify specific classes of variants with a higher 298 
burden in diseased individuals36; 45; 46. We used a version of the scores derived from the non-299 
neuropsychiatric subset of the Exome Aggregation Consortium (ExAC) samples. Because some 300 
of our control cohorts are also in ExAC (Table S2), we restricted our constrained gene burden 301 
tests to controls outside of the ExAC cohort (N=4,042).  302 
Consistent with a recent study that evaluated de novo burden in autism46, burden signals 303 
of PTVs were mostly contained in genes with a pLI > 0.995 compared to pLI > 0.9 (Figures S12 304 
& S13). Focusing on pLI > 0.995 in the all-epilepsy case-control analysis, both protein-truncating 305 
and damaging missense (MPC35≥2) URVs in LoF-intolerant genes showed a mutational burden 306 
with an odds ratio of 1.3 (adjP = 1.6×10-4) and 1.1 (adjP = 0.039), respectively. Breaking this 307 
down by epilepsy types, there was a significant excess of these deleterious URVs among 308 
individuals with DEE (ORPTV = 1.4, adjPPTV = 0.013; ORMPC = 1.2, adjPMPC = 0.019), as expected. 309 
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This enrichment was also seen in individuals with GGE with a magnitude comparable to that in 310 
DEE (ORPTV = 1.4, adjPPTV = 9.1×10-5; ORMPC = 1.2, adjPMPC = 5.5×10-3), but was not significant 311 
in individuals with NAFE (ORPTV = 1.2, adjPPTV = 0.062; ORMPC =1.0, adjPMPC = 0.37; Figure 1). 312 
There was no evidence of excess burden in synonymous URVs, suggesting that enrichment of 313 
deleterious pathogenic variants was unlikely to be the result of un-modeled population 314 
stratification or technical artifact. Among in-silico missense predictors, MPC≥2 annotations 315 
consistently showed a higher burden than those predicted by PolyPhen-2 and SIFT. The burden 316 
among missense-constrained genes exhibited a similar pattern, with PTVs showing a higher 317 
burden in DEE than in GGE and NAFE (Figure S14). In addition, both large gene sets were more 318 
enriched for PTVs than for damaging missense variants. 319 
 320 
Burden in candidate genetic etiologies associated with epilepsy 321 
Among URVs in previously reported epilepsy genes, we found an expected and pronounced 322 
difference in the number of singleton protein-truncating URVs in individuals with DEE relative to 323 
controls. PTVs were associated with an increased DEE risk in 43 known dominant epilepsy 324 
genes24 (OR = 6.3, adjP = 2.1×10-08), 50 known dominant DEE genes10 (OR = 9.1, adjP = 7.8×10-325 
11), and 33 genes with de novo burden in neurodevelopmental disorders with epilepsy10 (OR = 326 
14.8, adjP =1.7×10-12). Evidence for an excess of ultra-rare PTVs was also observed in individuals 327 
with GGE, with an odds ratio ranging from 2 to 4. No enrichment of PTVs was observed among 328 
people with NAFE (Figure 2A; Table S9). In contrast, the burden of singleton missense (MPC≥2) 329 
URVs was more pervasive across epilepsy types. Compared to controls, there was a 3.6-fold 330 
higher rate of these missense URVs in established epilepsy genes in individuals with DEE (adjP 331 
= 1.6×10-10), a 2.3-fold elevation in individuals with GGE (adjP = 6.4×10-07), and a 1.9-fold 332 
elevation in individuals with NAFE (adjP = 2.8×10-4).  333 
 334 
Burden in genes encoding for cation channels and neurotransmitter receptors 335 
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Among brain-enriched genes—those defined as genes with at least a 2-fold increase in 336 
expression in brain tissues relative to their average expression across tissues based on GTEx 337 
data40—both protein-truncating and damaging missense (MPC≥2) URVs were significantly 338 
enriched in epilepsy cases versus controls, and the missense burden was much higher than the 339 
PTV burden (Figure S15). We then investigated the burden in four smaller gene sets previously 340 
implicated as mechanisms driving the etiology of epilepsy; these included 19 genes encoding 341 
GABAA receptor subunits, 113 genes involved in GABAergic pathways, 34 genes encoding 342 
excitatory receptors (ionotropic glutamate receptor subunits and nicotinic acetylcholine receptor 343 
subunits), and 86 voltage-gated cation channel genes (e.g., sodium, potassium, calcium—full  list 344 
in Table S6)25. We discovered that, relative to damaging missense variants, the distribution of 345 
PTVs in most of these gene sets did not differ significantly between epilepsy cases and controls 346 
(Figure 2A; Table 1). The PTV signals that remained significant after FDR correction included, 347 
for individuals with DEE, an increased burden in GABAergic pathway genes and voltage-gated 348 
cation channels, and noticeably, for individuals with GGE, an increased burden in the inhibitory 349 
GABAA receptors (OR = 4.8, adjP = 0.021). No PTV burden was detected for individuals with 350 
NAFE. In contrast, the enrichment of missense (MPC≥2) URVs was more extensive in these gene 351 
sets across all epilepsy-control comparisons (Figure 2A; Table 1). The burden of these damaging 352 
missense pathogenic variants was seen in GABAA receptor genes (ORDEE = 3.7, adjPDEE = 0.028; 353 
ORGGE = 3.8, adjPGGE = 1.4×10-3; ORNAFE = 2.7, adjPNAFE = 0.039), GABAergic pathway genes 354 
(ORDEE = 2.6, adjPDEE = 4.7×10-5; ORGGE = 1.9, adjPGGE = 9.9×10-04; ORNAFE = 1.4, adjPNAFE = 355 
0.11), and voltage-gated cation channel genes (ORDEE = 2.1, adjPDEE = 1.7×10-03; ORGGE = 1.5, 356 
adjPGGE = 0.023; ORNAFE = 1.4, adjPNAFE = 0.081). However, no enrichment was detected in genes 357 
encoding excitatory receptors. For individuals with NAFE, the burden signals were consistently 358 
the weakest across gene sets compared to the other epilepsy phenotypes. None of the gene sets 359 
was enriched for putatively neutral variation, except for a slightly elevated synonymous burden in 360 
GABAA receptor genes (Table S9). These results support a recent finding where rare missense 361 
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variation in GABAA receptor genes conferred a significant risk to GGE25, and together implicate 362 
the relative importance and involvement of damaging missense variants in abnormal inhibitory 363 
neurotransmission in both severe and less severe forms of epilepsy. 364 
For gene sets other than the three lists of previously associated genes (Table S6; 74 non-365 
overlapping genes in total), we evaluated the residual burden of URVs after correcting for events 366 
in the 74 known genes. For the gene sets of cation channel and neurotransmitter receptor genes, 367 
the adjusted burden signals of singleton deleterious URVs was largely reduced, with some weak 368 
associations remaining in GABAA receptor-encoding or GABAergic genes among individuals with 369 
DEE or GGE. For the larger gene groups of constrained genes and brain-enriched genes, burden 370 
signals were attenuated but many remained significant, especially the strong enrichment of 371 
missense MPC≥2 variants in brain-enriched genes across all three classes of epilepsy (Figure 372 
S16). These findings suggest that although most gene burden is driven by previously identified 373 
genes, more associations could be uncovered with larger sample sizes. 374 
 375 
Gene-based collapsing analysis recapture known genes for DEE 376 
For gene discovery, because both protein-truncating and damaging missense (MPC≥2) URVs 377 
showed an elevated burden in epilepsy cases, we aggregated both together as deleterious 378 
pathogenic variants along with in-frame insertions and deletions in our gene collapsing analysis. 379 
This amassed to a total of 46,917 singleton URVs and 52,416 URVs with AC≤3.  Surprisingly, 380 
for individuals diagnosed with DEE, we re-identified several of the established candidate DEE 381 
genes as top associations (Figure 3A). Although screening was not performed systematically, 382 
many DEE patients were screened-negative using clinical gene panels prior to enrollment (Table 383 
S7). Based on the results of singleton URVs, SCN1A was the only gene that reached exome-384 
wide significance (OR = 18.4, P = 5.8×10-8); other top-ranking known genes included NEXMIF 385 
(previously known as KIAA2022; OR > 99, P = 1.6×10-6), KCNB1 (OR = 20.8, P = 2.5×10-4), 386 
SCN8A (OR = 13.8, P = 6.1×10-4), and SLC6A1 (OR = 11.1, P = 3.6×10-3) (Table S11). Some 387 
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carriers of deleterious URVs in lead genes were affected individuals with a normal result for gene 388 
panel testing, such as 2 out of the 3 carriers of qualifying URVs for PURA and 2 out of 5 for 389 
KCNB1 (Table S7). This is primarily because gene panels ordered for a particular diagnosis 390 
usually do not screen all of the commonly implicated DEE genes (e.g., one of the carriers of 391 
qualifying URVs in KCNB1 was diagnosed with West syndrome and screened with a customized 392 
panel that did not include KCNB1).  Overall, more than 50 different gene panels were used across 393 
sample-contributing sites, which adds to the heterogeneity in screening procedures and 394 
interpretation. The gene burden results held up when considering URVs with AC≤3, often showing 395 
even stronger associations; two other well-studied genes, STXBP1 (OR = 13.3, P = 1.4×10-5) and 396 
WDR45 (OR > 49, P = 1.2×10-3), emerged on top, both of which have been implicated in DEE 397 
and developmental disorders (Table S12). 398 
 399 
Channel and transporter genes implicated in GGE and NAFE 400 
When evaluating gene burden in the GGE and NAFE epilepsy subgroups, we did not identify any 401 
exome-wide significant genes. However, several candidate epilepsy genes made up the lead 402 
associations, including ion channel and transporter genes, mutations of which are known to cause 403 
rare forms of epilepsy. For the GGE case-control analysis in singleton deleterious URVs, the lead 404 
associations included four previously-associated genes (EEF1A2, OR = 32, P = 3.8 × 10-4; 405 
GABRG2, OR = 19.0, P = 6.2×10-4; SLC6A1, OR = 7.3, P = 2.0×10-3; and GABRA1, OR = 9.5, P 406 
= 2.2×10-3), and two genes (CACNA1G, OR = 9.1, P = 2.5×10-4; UNC79, OR = 19.0, P = 6.2×10-407 
4) that were not previously linked to epilepsy but are both highly expressed in the brain and under 408 
evolutionary constraint (Figures 3B; Table S13). Although evidence has been mixed, CACNA1G 409 
was previously implicated as a potential susceptibility gene for GGE in mutational analysis47 and 410 
reported to modify mutated sodium channel (SCN2A) activity in epilepsy48. UNC79 is an essential 411 
part of the UNC79-UNC80-NALCN channel complex that influences neuronal excitability by 412 
interacting with extracellular calcium ions49, and this channel complex has been previously 413 
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associated with infantile encephalopathy50. Notably, all these lead genes were more enriched for 414 
damaging missense (MPC≥2) than for protein-truncating URVs despite the lower rate of MPC≥2 415 
variants relative to PTVs (Table S13).  416 
For individuals with NAFE, the analysis of singleton deleterious URVs identified LGI1 and 417 
TRIM3 as the top two genes carrying a disproportionate number of deleterious URVs, however 418 
neither reached exome-wide significance (OR > 32, P = 2.1×10-4). GABRG2, a lead association 419 
in individuals with GGE, was among the top ten most enriched genes, along with two brain-420 
enriched, constrained genes (PPFIA3, OR = 8.2, P = 4.2×10-3; and KCNJ3, OR = 16.4, P = 421 
1.2×10-3). GABRG2 has previously been reported to show an enrichment of variants compared 422 
to controls in a cohort of individuals with Rolandic epilepsy (childhood epilepsy with 423 
centrotemporal spikes) or related phenotypes, the most common group of focal epilepsies of 424 
childhood51. Two other genes previously associated with epilepsy, DEPDC5 and SCN8A (both 425 
OR = 5.5, P = 0.01), were among the top twenty associations (Figures 3C; Table S14). LGI1 and 426 
DEPDC5 are established genes for focal epilepsy, and DEPDC5 was the only exome-wide 427 
significant hit in the Epi4K WES study for familial NAFE cases24. TRIM3 has not been previously 428 
implicated in epilepsy, but evidence from a mouse model study implicates it in regulation of 429 
GABAA receptor signaling and thus modulation of seizure susceptibility52. Single gene burden for 430 
both GGE and NAFE remained similar when considering URVs with an allele count up to AC≤3 431 
(Tables S14 & S16). Gene burden tests collapsing all epilepsy phenotypes recapitulated the lead 432 
genes in each of the subgroup-specific analyses, but none of the genes achieved exome-wide 433 
significance (Tables S17 & S18). It is worth noting that some of the genes were enriched for 434 
deleterious URVs among the “controls”, which is clearly driven by non-neuropsychiatric disease 435 
ascertainment for many of the available controls (e.g., LDLR in Table S17; most control carriers 436 
were individuals with cardiovascular diseases from the MIGen cohorts in Table S2). Thus, these 437 
should not be interpreted as potential protective signals for epilepsy. 438 
 439 
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Recessive model, SKAT gene test, and single variant association 440 
The secondary gene-based test of a recessive model did not identify genes that differed 441 
significantly in the carrier rate of homozygous deleterious variants between epilepsy-affected 442 
individuals and controls (Table S19). Even if we considered variants up to MAF < 0.01, for most 443 
of the lead genes, only one case carrier was identified. For the DEE cohort, these genes included 444 
recessive genes previously implicated, such as ARV1, BRAT1, CHRDL53 with a homozygous PTV 445 
and OPHN153 with a recessive missense (MPC≥2) variant (Table S19A). For the GGE and NAFE 446 
cohorts, a few studied recessive epilepsy genes were also observed in the lead gene associations, 447 
such as SLC6A853 (a homozygous PTV) for GGE (Table S19B), and SLC6A8 (a homozygous 448 
missense-MPC) and SYN153 (a homozygous PTV) for NAFE (Table S19C). One GGE-affected 449 
individual was found homozygous for an in-frame deletion on CHD2, a dominant DEE gene53 450 
(Table S19B). These findings suggest an even larger cohort will be needed to identify with clarity 451 
recessive risk variants for different groups of epilepsy. 452 
Beyond URVs, we studied the contribution of low frequency deleterious variants to 453 
epilepsy risk using SKAT (MAF < 0.01). Top associations for individuals with DEE included known 454 
genes, such as missense-enriched STXBP1 (P = 9.3×10-9), KCNA2 (P = 1.0×10-5; Figure S18), 455 
and PTV-enriched NEXMIF (P = 7.1×10-8), and SCN1A (P = 3.9×10-4; Figure S19). However, no 456 
significant gene enrichment was observed for GGE and NAFE or when combining all epilepsy 457 
cases. The tests for PTVs and missense variants with MPC≥2 were mostly underpowered due to 458 
sparse observations (Figure S18 & S19).  No individual low-frequency variant (MAF > 0.001) was 459 
significantly associated with overall epilepsy or with any of the studied epilepsy phenotypes 460 
(Figure S20). The primary gene-based test results and single variant associations are available 461 
on our Epi25 WES browser (Web Resources).  462 
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Discussion 463 
In the largest exome study of epilepsies to date, we show that ultra-rare deleterious coding 464 
variation—variation absent in a large population-based exome database—is enriched across the 465 
severity spectrum for epilepsy syndromes when compared to ancestrally matched controls. When 466 
all genes were considered in the tested gene sets, PTVs showed a more significant signal than 467 
missense variants with an MPC≥2, and enrichment in deleterious URVs was more pronounced in 468 
individuals diagnosed with DEE and GGE relative to NAFE. While no single gene surpassed 469 
exome-wide statistical significance for GGE or NAFE, specific gene sets that had previously been 470 
associated with epilepsy or encoding biologically interesting entities showed a clear enrichment 471 
of deleterious URVs. Specifically, we observed a significant excess of deleterious URVs in 472 
constrained genes, established epilepsy genes, and GABAA receptor subunit genes, a larger 473 
group of genes delineating the GABAergic pathway, and also all cation channel-encoding genes. 474 
Our results thus support the concept that defects in GABAergic inhibition underlie various forms 475 
of epilepsy. The epilepsy-associated excess of deleterious URVs in our study likely comprises 476 
signals from both inherited and de novo variants, the latter enriched by restricting variant inclusion 477 
to a combination of study-specific singletons and absence in a population reference cohort 478 
(DiscovEHR)38; 45. These findings, based on a more than 5-fold increase in sample size over 479 
previous exome-sequencing studies24-26; 54, clearly support observations that have been 480 
hypothesized for GGE and NAFE from studies of rare, large monogenic families, and confirm that 481 
the same genes are relevant in both settings. Thus, a further increase in sample size will continue 482 
to unravel the complex genetic architecture of GGE and NAFE. The evidence that URVs 483 
contribute, in part, to GGE and NAFE is clear, but what remains unclear is the extent to which the 484 
excess rate of URVs observed in cases is a consequence of a small subset of patients carrying 485 
highly penetrant mutations versus URVs that are conferring risk, but do not rise to the level of 486 
Mendelian acting mutations but rather simply contribute to an overall polygenic risk for these 487 
syndromes. Interestingly, no enrichment was seen in genes encoding the excitatory glutamate 488 
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and acetylcholine receptors. For GGE, this difference between variants in inhibitory versus 489 
excitatory receptor genes may be real, as excitatory receptor variants have not been shown so 490 
far in single subjects or families. In NAFE, however, we suspect it is probably due to a lack of 491 
power and/or genetic heterogeneity, since genetic variants in specific subunits of nicotinic 492 
acetylcholine and NMDA receptors have been described extensively in different types of non-493 
acquired familial focal epilepsies55.  494 
Notably, our overall finding of a mild to moderate burden of deleterious coding URVs in 495 
NAFE (Figure 1 & 2) contrasts with results reported in the Epi4K WES study, where the familial 496 
NAFE cohort showed a strong enrichment signal of ultra-rare functional variation in known 497 
epilepsy genes and ion channel genes24. In addition, our findings for GGE showed a genetic risk 498 
comparable or even stronger than the Epi4K familial GGE cohort. The strong signal in our GGE 499 
cohort likely reflects the larger sample size, whereas the weaker signal in our NAFE cohort is 500 
most likely due to differences in patient ascertainment. In Epi4K the cohort was deliberately 501 
enriched with familial cases, most of whom had an affected first-degree relative and were 502 
ascertained in sibling or parent-child pairs ors multiplex families, and familial NAFE is relatively 503 
uncommon. In the Epi25 collaboration a positive family history of epilepsy was not a requirement 504 
and only 9% of DEE, 12% of GGE, and 5% of NAFE patients had a known affected first-degree 505 
relative. Removing these familial cases led to no change in gene set burden (Figure S17) and a 506 
slightly attenuated association for some of the lead genes in the GGE and NAFE cohorts (Table 507 
S20). Indeed, our results were consistent with the Epi4K sporadic NAFE cohort, where no signals 508 
of enrichment were observed24; 56. This difference may reflect the substantial etiological and 509 
genetic heterogeneity of epilepsy even within subgroups especially in NAFE. In particular, the 510 
dramatically weaker genetic signals, per sample, observed in individuals with NAFE studied here 511 
compared with those in the previous Epi4K study illustrate a pronounced difference in the genetic 512 
signals associated with familial and non-familial NAFE. The reasons for this striking difference 513 
remain to be elucidated. Comparing GGE and NAFE, our findings showed a larger genetic burden 514 
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from URVs for GGE relative to NAFE, which could be due to heterogeneity in electroclinical 515 
syndromes within each class and should not be viewed as conclusive. On the other hand, in the 516 
latest GWAS of common epilepsies of 15,212 cases and 29,677 controls from the ILAE 517 
Consortium20, fewer GWAS hits were discovered and less heritability was explained by common 518 
genetic variation for the focal epilepsy cohort (9.2%) compared to the GGE cohort (32.1%), 519 
suggesting that current evidence from both common and rare variant studies are converging on 520 
a larger genetic component underlying the etiology of non-familial cases of GGE relative to NAFE, 521 
as originally postulated. 522 
We found that ultra-rare missense variants with an MPC score35 ≥ 2 (2.0% of missense 523 
variants) were enriched in individuals with epilepsy at an effect size approaching PTVs in the 524 
investigated gene groups. For GGE and NAFE, the burden of these missense variants (MPC≥2) 525 
was even more prominent than PTVs in known epilepsy genes and GABAergic genes (Figure 2). 526 
At the gene level, some of the most commonly implicated channel genes (e.g. GABRG2, 527 
CACNA1G) carried a higher number of missense variants (MPC≥2) than PTVs in people with 528 
epilepsy. For instance, in the gene-based collapsing analysis considering all epilepsies, 15 529 
GABRG2 pathogenic variants were found in epilepsy-affected individuals (including 7 GGE and 530 
7 NAFE; Tables S13, 15 & 17) versus only 1 pathogenic variant in controls; among the case-531 
specific pathogenic variants, one was a splice site mutation, while the other 14 were all missense 532 
variants (MPC≥2) (Figure S21), linking to an impaired channel function. This is in line with findings 533 
from a recent exome-wide study of 6,753 individuals with neurodevelopmental disorder with and 534 
without epilepsy10 that detected an association of missense de novo variants with the presence 535 
of epilepsy, particularly when considering only ion channel genes. A disease-association of 536 
missense variants rather than PTVs points to a pathophysiological mechanism of protein-537 
alteration (e.g., gain-of-function or dominant-negative effects) rather than haploinsufficiency, but 538 
ultimately only functional tests can elucidate these mechanisms. A recent study on the molecular 539 
basis of 6 de novo missense variants in GABRG2 identified in DEE reported an overall reduced 540 
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inhibitory function of GABRG2 due to decreased cell surface expression or GABA-evoked current 541 
amplitudes, suggesting GABAergic disinhibition as the underlying mechanism57. Surprisingly, 2 542 
of those recurrent de novo missense variants were seen in two GGE-affected individuals in our 543 
study (A106T and R323Q), and another recently reported variant in GABRB2 (V316I) also 544 
occurred both de novo in DEE58 and as an inherited variant in a GGE family showing a loss of 545 
receptor function25. This suggests that changes in protein function from the same missense 546 
pathogenic variant may contribute to not only severe epilepsy syndromes but also epilepsy 547 
phenotypes with milder presentations, similar to what is known about variable expressivity in large 548 
families carrying GABRG2 variants55; 59-61. Reduced receptor function due to GABRG2 variants 549 
has been also shown for childhood epilepsy with centrotemporal spikes previously51; 61, which 550 
belong to the NAFE group in this study. Moving forward, discovering how variant-specific 551 
perturbations of the neurotransmission and signaling system in a gene can link to a spectrum of 552 
epilepsy syndromes will require in-depth functional investigation. 553 
Although we have increased the sample size from the Epi4K and EuroEPINOMICS WES 554 
studies for both GGE and NAFE subgroups by more than 5-fold, the phenotypic and genetic 555 
heterogeneity of these less severe forms of epilepsy—on par with other complex neurological and 556 
neuropsychiatric conditions—will require many more samples to achieve statistical power for 557 
identifying exome-wide significant genes. We estimated that at least 8,000 cases and 20,000 558 
controls would be required to convert some of the lead genes from the GGE and NAFE cohorts 559 
to exome-wide significance (Table S8). Furthermore, while we implemented stringent QC to 560 
effectively control for the exome capture differences between cases and controls, this 561 
concomitantly resulted in a loss of a substantial amount of the called sites and reduced our 562 
detection power to identify associated variants. As sample sizes grow, the technical variation 563 
across projects and sample collections will remain a challenge in large-scale sequencing studies 564 
relying on a global collaborative effort. 565 
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With this largest epilepsy WES study to date, we demonstrated a strong replicability of 566 
existing gene findings in an independent cohort. GABAA receptor genes affected by predicted-567 
pathogenic missense pathogenic variants were enriched across the three subgroups of epilepsy. 568 
An ongoing debate in epilepsy genetics is the degree to which generalized and focal epilepsies 569 
segregate separately, and whether their genetic determinants are largely distinct or sometimes 570 
shared4; 22. Whilst clinical evidence for general separation of pathophysiological mechanisms in 571 
these two forms is strong, and most monogenic epilepsy families segregate either generalized or 572 
focal syndromes, the distinction is not absolute. Here, the finding of rare variants in GABAA 573 
receptor genes in both forms adds weight to the case for shared genetic determinants. 574 
Our results suggest that clinical presentations of GGE and NAFE with complex inheritance 575 
patterns have a combination of both common and rare genetic risk variants. The latest ILAE 576 
epilepsy GWAS of over 15,000 patients and 25,000 controls identified 16 genome-wide significant 577 
loci for common epilepsies20, mapped these loci to ion channel genes, transcriptional factors, and 578 
pyridoxine metabolism, and implicated a role in epigenetic regulation of gene expression in the 579 
brain. A combination of rare and common genetic association studies with large sample sizes, 580 
along with the growing evidence from studies of copy number variation and tandem repeat 581 
expansions in epilepsy23; 62; 63, will further decipher the genetic landscape of GGE and NAFE. The 582 
ongoing effort of the Epi25 collaborative is expected to double the patient cohorts in upcoming 583 
years with the goal of elucidating shared and distinct gene discoveries for severe and less severe 584 
forms of epilepsy, ultimately facilitating precision medicine strategies in the treatment of epilepsy.  585 
25 
Supplemental Data 586 
Supplemental data includes affiliations of the contributing authors, descriptions of patient 587 
recruitment and phenotyping from individual participating cohorts, supplemental acknowledgment, 588 
21 figures and 20 tables. 589 
 590 
Consortia  591 
A full list of contributing authors: 592 
Yen-Chen Anne Feng, Daniel P. Howrigan, Liam E. Abbott, Katherine Tashman, Felecia Cerrato, 593 
Tarjinder Singh, Henrike Heyne, Andrea Byrnes, Claire Churchhouse, Nick Watts, Matthew 594 
Solomonson, Dennis Lal, Erin L. Heinzen, Ryan S. Dhindsa, Kate E. Stanley, Gianpiero L. 595 
Cavalleri, Hakon Hakonarson, Ingo Helbig, Roland Krause, Patrick May, Sarah Weckhuysen, 596 
Slavé Petrovski, Sitharthan Kamalakaran, Sanjay M. Sisodiya, Patrick Cossette, Chris Cotsapas, 597 
Peter De Jonghe, Tracy Dixon-Salazar, Renzo Guerrini,  Patrick Kwan, Anthony G. Marson, 598 
Randy Stewart, Chantal Depondt, Dennis J. Dlugos, Ingrid E. Scheffer, Pasquale Striano, 599 
Catharine Freyer, Kevin McKenna, Brigid M. Regan, Susannah T. Bellows, Costin Leu, Caitlin A. 600 
Bennett, Esther M.C. Johns, Alexandra Macdonald, Hannah Shilling, Rosemary Burgess, Dorien 601 
Weckhuysen, Melanie Bahlo, Terence J. O'Brien, Marian Todaro, Hannah Stamberger, Danielle 602 
M. Andrade, Tara R. Sadoway, Kelly Mo, Heinz Krestel, Sabina Gallati, Savvas S. Papacostas, 603 
Ioanna Kousiappa, George A. Tanteles, Katalin Štěrbová, Markéta Vlčková, Lucie Sedláčková, 604 
Petra Laššuthová, Karl Martin Klein, Felix Rosenow, Philipp S. Reif, Susanne Knake, Wolfram S. 605 
Kunz, Gábor Zsurka, Christian E. Elger, Jürgen Bauer, Michael Rademacher, Manuela 606 
Pendziwiat, Hiltrud Muhle, Annika Rademacher, Andreas van Baalen, Sarah von Spiczak, Ulrich 607 
Stephani, Zaid Afawi, Amos D. Korczyn, Moien Kanaan, Christina Canavati, Gerhard Kurlemann, 608 
Karen Müller-Schlüter, Gerhard Kluger, Martin Häusler, Ilan Blatt, Johannes R. Lemke, Ilona Krey, 609 
Yvonne G. Weber, Stefan Wolking, Felicitas Becker, Christian Hengsbach, Sarah Rau, Ana F. 610 
Maisch, Bernhard J. Steinhoff, Andreas Schulze-Bonhage, Susanne Schubert-Bast, Herbert 611 
26 
Schreiber, Ingo Borggräfe, Christoph J. Schankin, Thomas Mayer, Rudolf Korinthenberg, Knut 612 
Brockmann, Gerhard Kurlemann, Dieter Dennig, Rene Madeleyn, Reetta Kälviäinen, Pia Auvinen, 613 
Anni Saarela, Tarja Linnankivi, Anna-Elina Lehesjoki, Mark I. Rees, Seo-Kyung Chung, William 614 
O. Pickrell, Robert Powell, Natascha Schneider, Simona Balestrini, Sara Zagaglia, Vera Braatz, 615 
Michael R. Johnson, Pauls Auce, Graeme J. Sills, Larry W. Baum, Pak C. Sham, Stacey S. 616 
Cherny, Colin H.T. Lui, Nina Barišić, Norman Delanty, Colin P. Doherty, Arif Shukralla, Mark 617 
McCormack, Hany El-Naggar, Laura Canafoglia, Silvana Franceschetti, Barbara Castellotti, 618 
Tiziana Granata, Federico Zara, Michele Iacomino, Francesca Madia, Maria Stella Vari, Maria 619 
Margherita Mancardi, Vincenzo Salpietro, Francesca Bisulli, Paolo Tinuper, Laura Licchetta, 620 
Tommaso Pippucci, Carlotta Stipa, Raffaella Minardi, Antonio Gambardella, Angelo Labate, 621 
Grazia Annesi, Lorella Manna, Monica Gagliardi, Elena Parrini, Davide Mei, Annalisa Vetro, 622 
Claudia Bianchini, Martino Montomoli, Viola Doccini, Carla Marini, Toshimitsu Suzuki, Yushi Inoue, 623 
Kazuhiro Yamakawa, Birute Tumiene, Lynette G. Sadleir, Chontelle King, Emily Mountier, S. 624 
Hande Caglayan, Mutluay Arslan, Zuhal Yapıcı, Uluc Yis, Pınar Topaloglu, Bulent Kara, Dilsad 625 
Turkdogan, Aslı Gundogdu-Eken, Nerses Bebek, Sibel Uğur-İşeri, Betül Baykan, Barış Salman, 626 
Garen Haryanyan, Emrah Yücesan, Yeşim Kesim, Çiğdem Özkara, Annapurna Poduri, Beth R. 627 
Shiedley, Catherine Shain, Russell J. Buono, Thomas N. Ferraro, Michael R. Sperling, Warren 628 
Lo, Michael Privitera, Jacqueline A. French, Steven Schachter, Ruben I. Kuzniecky, Orrin 629 
Devinsky, Manu Hegde, Pouya Khankhanian, Katherine L. Helbig, Colin A. Ellis, 630 
Gianfranco Spalletta, Fabrizio Piras, Federica Piras, Tommaso Gili, Valentina Ciullo, Andreas 631 
Reif, Andrew McQuillin, Nick Bass, Andrew McIntosh, Douglas Blackwood, Mandy Johnstone, 632 
Aarno Palotie, Michele T. Pato, Carlos N. Pato, Evelyn J. Bromet, Celia Barreto Carvalho, Eric D. 633 
Achtyes, Maria Helena Azevedo, Roman Kotov, Douglas S. Lehrer, Dolores Malaspina, Stephen 634 
R. Marder, Helena Medeiros, Christopher P. Morley, Diana O. Perkins, Janet L. Sobell, Peter F. 635 
Buckley, Fabio Macciardi, Mark H. Rapaport, James A. Knowles, Genomic Psychiatry Cohort 636 
(GPC) Consortium, Ayman H. Fanous, Steven A. McCarroll, Namrata Gupta, Stacey B. Gabriel, 637 
27 
Mark J. Daly, Eric S. Lander, Daniel H. Lowenstein, David B. Goldstein, Holger Lerche, 638 
Samuel F. Berkovic, and Benjamin M. Neale 639 
Author contributions: 640 
S.F.B., H.L., D.B.G., and D.H.L conceived the consortium and contributed to the study design.  641 
S.F.B., C.D., D.J.D., D.H.L., A.G.M., I.E.S., and P.S. designed patient recruitment and 642 
phenotyping criteria. D.H.L., D.B.G., H.L., S.F.B, C.D., D.J.D., A.G.M., I.E.S., P.S, C.F., R.K., 643 
K.M., B.M.R., S.T.B., G.L.C., P.C., C.C., P.D.G., T.D-S., R.G., H.H., E.L.H., I.H., P.K., S.P., 644 
S.M.S., R.S., and S.W. advised and approved the consortium activities. Authors from individual 645 
patient and control cohorts (Supplemental Data) contributed to site-specific recruitment and 646 
phenotyping. B.M.N., M.J.D., D.P.H., and F.C. directed and managed sample aggregation and 647 
sequencing effort at the Broad Institute. Sequence data generation was directed by S.B.G and 648 
managed by F.C. and N.G., with E.S.L, M.J.D., and B.M.N. overseeing the work. B.M.N, 649 
D.B.G., C.C., D.L, L.E.A., M.J.D., E.L.H., G.L.C., H.H., H.L., I.H., R.K., S.W., S.K., and S.P. 650 
supervised and reviewed genetic data analyses. Lead analyst Y.A.F. conducted the analyses 651 
with D.P.H, L.E.A., and K.T. Y.A.F. wrote the manuscript and interpreted the results with B.M.N., 652 
D.P.H., E.S.L., S.F.B., H.L., D.B.G., E.L.H., and D.H.L.  653 
 654 
Acknowledgments 655 
We gratefully thank the Epi25 principal investigators, local staff from individual cohorts, and all of 656 
the patients with epilepsy who participated in the study for making possible this global 657 
collaboration and resource to advance epilepsy genetics research. This work is part of the Centers 658 
for Common Disease Genomics (CCDG) program, funded by the National Human Genome 659 
Research Institute (NHGRI) and the National Heart, Lung, and Blood Institute (NHLBI). CCDG 660 
research activities at the Broad Institute was supported by NHGRI grant UM1 HG008895. The 661 
Genome Sequencing Program efforts were also supported by NHGRI grant 5U01HG009088-02. 662 
28 
The content is solely the responsibility of the authors and does not necessarily represent the 663 
official views of the National Institutes of Health. Supplemental grant for Epi25 phenotyping was 664 
supported by “Epi25 Clinical Phenotyping R03”, National Institutes of Health (1R03NS108145-665 
01), with D.H.L and S.F.B as the principal investigators. Additional funding sources and 666 
acknowledgment of individual patient and control cohorts were listed in Supplemental Data. We 667 
thank the Stanley Center for Psychiatric Research at the Broad Institute for supporting sequencing 668 
effort and control sample aggregation. The authors would like to thank the Discov-EHR 669 
collaboration of Geisinger Health System and Regeneron for providing exome variant data for 670 
comparison. We also thank Sali Farhan, Kyle Satterstrom, and Chai-Yen Chen for helpful 671 
discussions, Nick Watts and Matthew Solomonson for browser development, and the Hail team 672 
for analysis support. 673 
 674 
Web Resources 675 
The URLs for the consortium, data, and results presented herein are as follows: 676 
Epi25 Collaborative, http://epi-25.org/ 677 
Exome Aggregation Consortium (ExAC), http://exac.broadinstitute.org 678 
The DiscovEHR cohort, http://www.discovehrshare.com 679 
Epi25 Year1 whole-exome sequence data on dbGaP, http://www.ncbi.nlm.nih.gov/gap through 680 
accession number phs001489 (the current study includes Year1-2 samples, and the Year2 data 681 
will later be made available) 682 
Epi25 WES results browser, http://epi25.broadinstitute.org/  683 
29 
References 684 
1. Fiest, K.M., Sauro, K.M., Wiebe, S., Patten, S.B., Kwon, C.S., Dykeman, J., Pringsheim, T., 685 
Lorenzetti, D.L., and Jette, N. (2017). Prevalence and incidence of epilepsy: A systematic 686 
review and meta-analysis of international studies. Neurology 88, 296-303. 687 
2. Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E., Engel, J., Jr., 688 
Forsgren, L., French, J.A., Glynn, M., et al. (2014). ILAE official report: a practical clinical 689 
definition of epilepsy. Epilepsia 55, 475-482. 690 
3. Annegers, J.F., Hauser, W.A., Anderson, V.E., and Kurland, L.T. (1982). The risks of seizure 691 
disorders among relatives of patients with childhood onset epilepsy. Neurology 32, 174-179. 692 
4. Berkovic, S.F., Howell, R.A., Hay, D.A., and Hopper, J.L. (1998). Epilepsies in twins: genetics of 693 
the major epilepsy syndromes. Ann Neurol 43, 435-445. 694 
5. Helbig, I., Scheffer, I.E., Mulley, J.C., and Berkovic, S.F. (2008). Navigating the channels and 695 
beyond: unravelling the genetics of the epilepsies. Lancet Neurol 7, 231-245. 696 
6. Hildebrand, M.S., Dahl, H.H., Damiano, J.A., Smith, R.J., Scheffer, I.E., and Berkovic, S.F. (2013). 697 
Recent advances in the molecular genetics of epilepsy. J Med Genet 50, 271-279. 698 
7. Epi4K Consortium. (2016). De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes 699 
of Epileptic Encephalopathies. Am J Hum Genet 99, 287-298. 700 
8. Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen, A.S., Berkovic, S.F., Cossette, P., 701 
Delanty, N., Dlugos, D., Eichler, E.E., Epstein, M.P., Glauser, T., et al. (2013). De novo 702 
mutations in epileptic encephalopathies. Nature 501, 217-221. 703 
9. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, and Epi4K Consortium. 704 
(2014). De novo mutations in synaptic transmission genes including DNM1 cause epileptic 705 
encephalopathies. Am J Hum Genet 95, 360-370. 706 
10. Heyne, H.O., Singh, T., Stamberger, H., Abou Jamra, R., Caglayan, H., Craiu, D., De Jonghe, 707 
P., Guerrini, R., Helbig, K.L., Koeleman, B.P.C., et al. (2018). De novo variants in 708 
neurodevelopmental disorders with epilepsy. Nat Genet 50, 1048-1053. 709 
11. McTague, A., Howell, K.B., Cross, J.H., Kurian, M.A., and Scheffer, I.E. (2016). The genetic 710 
landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 15, 711 
304-316. 712 
12. Howell, K.B., Eggers, S., Dalziel, K., Riseley, J., Mandelstam, S., Myers, C.T., McMahon, J.M., 713 
Schneider, A., Carvill, G.L., Mefford, H.C., et al. (2018). A population-based cost-714 
effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia 59, 715 
1177-1187. 716 
13. Banerjee, P.N., Filippi, D., and Allen Hauser, W. (2009). The descriptive epidemiology of 717 
epilepsy-a review. Epilepsy Res 85, 31-45. 718 
14. Camfield, P., and Camfield, C. (2015). Incidence, prevalence and aetiology of seizures and 719 
epilepsy in children. Epileptic Disord 17, 117-123. 720 
15. Jallon, P., Loiseau, P., and Loiseau, J. (2001). Newly diagnosed unprovoked epileptic seizures: 721 
presentation at diagnosis in CAROLE study. Coordination Active du Reseau Observatoire 722 
Longitudinal de l' Epilepsie. Epilepsia 42, 464-475. 723 
16. Jallon, P., and Latour, P. (2005). Epidemiology of idiopathic generalized epilepsies. Epilepsia 46 724 
Suppl 9, 10-14. 725 
17. EPICURE Consortium, Leu, C., de Kovel, C.G., Zara, F., Striano, P., Pezzella, M., Robbiano, A., 726 
Bianchi, A., Bisulli, F., Coppola, A., et al. (2012). Genome-wide linkage meta-analysis 727 
identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies. Epilepsia 728 
53, 308-318. 729 
18. Marini, C., Scheffer, I.E., Crossland, K.M., Grinton, B.E., Phillips, F.L., McMahon, J.M., Turner, 730 
S.J., Dean, J.T., Kivity, S., Mazarib, A., et al. (2004). Genetic architecture of idiopathic 731 
generalized epilepsy: clinical genetic analysis of 55 multiplex families. Epilepsia 45, 467-478. 732 
19. The International League Against Epilepsy Consortium on Complex Epilepsies. (2014). Genetic 733 
determinants of common epilepsies: a meta-analysis of genome-wide association studies. 734 
Lancet Neurol 13, 893-903. 735 
30 
20. The International League Against Epilepsy Consortium on Complex Epilepsies. (2018). Genome-736 
wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the 737 
common epilepsies. Nat Commun 9, 5269. 738 
21. Kjeldsen, M.J., Corey, L.A., Christensen, K., and Friis, M.L. (2003). Epileptic seizures and 739 
syndromes in twins: the importance of genetic factors. Epilepsy Res 55, 137-146. 740 
22. Peljto, A.L., Barker-Cummings, C., Vasoli, V.M., Leibson, C.L., Hauser, W.A., Buchhalter, J.R., 741 
and Ottman, R. (2014). Familial risk of epilepsy: a population-based study. Brain 137, 795-742 
805. 743 
23. Myers, C.T., and Mefford, H.C. (2015). Advancing epilepsy genetics in the genomic era. Genome 744 
Med 7, 91. 745 
24. Epi4K Consortium, and Epilepsy Phenome/Genome Project. (2017). Ultra-rare genetic variation 746 
in common epilepsies: a case-control sequencing study. Lancet Neurol 16, 135-143. 747 
25. May, P., Girard, S., Harrer, M., Bobbili, D.R., Schubert, J., Wolking, S., Becker, F., Lachance-748 
Touchette, P., Meloche, C., Gravel, M., et al. (2018). Rare coding variants in genes encoding 749 
GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. 750 
Lancet Neurol 17, 699-708. 751 
26. Heinzen, E.L., Depondt, C., Cavalleri, G.L., Ruzzo, E.K., Walley, N.M., Need, A.C., Ge, D., He, 752 
M., Cirulli, E.T., Zhao, Q., et al. (2012). Exome sequencing followed by large-scale 753 
genotyping fails to identify single rare variants of large effect in idiopathic generalized 754 
epilepsy. Am J Hum Genet 91, 293-302. 755 
27. Tan, N.C., and Berkovic, S.F. (2010). The Epilepsy Genetic Association Database (epiGAD): 756 
analysis of 165 genetic association studies, 1996-2008. Epilepsia 51, 686-689. 757 
28. Cavalleri, G.L., Lynch, J.M., Depondt, C., Burley, M.W., Wood, N.W., Sisodiya, S.M., and 758 
Goldstein, D.B. (2005). Failure to replicate previously reported genetic associations with 759 
sporadic temporal lobe epilepsy: where to from here? Brain 128, 1832-1840. 760 
29. Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guilhoto, L., Hirsch, E., 761 
Jain, S., Mathern, G.W., Moshe, S.L., et al. (2017). ILAE classification of the epilepsies: 762 
Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 763 
512-521. 764 
30. EPGP Collaborative, Abou-Khalil, B., Alldredge, B., Bautista, J., Berkovic, S., Bluvstein, J., Boro, 765 
A., Cascino, G., Consalvo, D., Cristofaro, S., et al. (2013). The epilepsy phenome/genome 766 
project. Clin Trials 10, 568-586. 767 
31. Van der Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., Del Angel, G., Levy-Moonshine, A., 768 
Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013). From FastQ data to high 769 
confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc 770 
Bioinformatics 43, 11 10 11-33. 771 
32. Li, H. (2014). Toward better understanding of artifacts in variant calling from high-coverage 772 
samples. Bioinformatics 30, 2843-2851. 773 
33. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R., Thormann, A., Flicek, P., and 774 
Cunningham, F. (2016). The Ensembl Variant Effect Predictor. Genome Biol 17, 122. 775 
34. Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., and 776 
Ruden, D.M. (2012). A program for annotating and predicting the effects of single nucleotide 777 
polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-778 
2; iso-3. Fly (Austin) 6, 80-92. 779 
35. Samocha, K.E., Kosmicki, J.A., Karczewski, K.J., O’Donnell-Luria, A.H., Pierce-Hoffman, E., 780 
MacArthur, D.G., Neale, B.M., and Daly, M.J. (2017). Regional missense constraint improves 781 
variant deleteriousness prediction. bioRxiv. 782 
36. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, 783 
A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al. (2016). Analysis of protein-coding genetic 784 
variation in 60,706 humans. Nature 536, 285-291. 785 
37. Dewey, F.E., Murray, M.F., Overton, J.D., Habegger, L., Leader, J.B., Fetterolf, S.N., 786 
O'Dushlaine, C., Van Hout, C.V., Staples, J., Gonzaga-Jauregui, C., et al. (2016). 787 
31 
Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from 788 
the DiscovEHR study. Science 354. 789 
38. Genovese, G., Fromer, M., Stahl, E.A., Ruderfer, D.M., Chambert, K., Landen, M., Moran, J.L., 790 
Purcell, S.M., Sklar, P., Sullivan, P.F., et al. (2016). Increased burden of ultra-rare protein-791 
altering variants among 4,877 individuals with schizophrenia. Nat Neurosci 19, 1433-1441. 792 
39. Samocha, K.E., Robinson, E.B., Sanders, S.J., Stevens, C., Sabo, A., McGrath, L.M., Kosmicki, 793 
J.A., Rehnstrom, K., Mallick, S., Kirby, A., et al. (2014). A framework for the interpretation of 794 
de novo mutation in human disease. Nat Genet 46, 944-950. 795 
40. Ganna, A., Genovese, G., Howrigan, D.P., Byrnes, A., Kurki, M., Zekavat, S.M., Whelan, C.W., 796 
Kals, M., Nivard, M.G., Bloemendal, A., et al. (2016). Ultra-rare disruptive and damaging 797 
mutations influence educational attainment in the general population. Nat Neurosci 19, 1563-798 
1565. 799 
41. Petrovski, S., and Wang, Q. (2016). QQperm: Permutation Based QQ Plot and Inflation Factor 800 
Estimation. R package version 1.0.1. https://CRANR-projectorg/package=QQperm. 801 
42. Wu, M.C., Lee, S., Cai, T., Li, Y., Boehnke, M., and Lin, X. (2011). Rare-variant association 802 
testing for sequencing data with the sequence kernel association test. Am J Hum Genet 89, 803 
82-93. 804 
43. Hail, https://github.com/hail-is/hail. 805 
44. Neale, B.M., Rivas, M.A., Voight, B.F., Altshuler, D., Devlin, B., Orho-Melander, M., Kathiresan, 806 
S., Purcell, S.M., Roeder, K., and Daly, M.J. (2011). Testing for an unusual distribution of 807 
rare variants. PLoS Genet 7, e1001322. 808 
45. Kosmicki, J.A., Samocha, K.E., Howrigan, D.P., Sanders, S.J., Slowikowski, K., Lek, M., 809 
Karczewski, K.J., Cutler, D.J., Devlin, B., Roeder, K., et al. (2017). Refining the role of de 810 
novo protein-truncating variants in neurodevelopmental disorders by using population 811 
reference samples. Nat Genet 49, 504-510. 812 
46. Satterstrom, F.K., Kosmicki, J.A., Wang, J., Breen, M.S., De Rubeis, S., An, J.-Y., Peng, M., 813 
Collins, R., Grove, J., Klei, L., et al. Novel genes for autism implicate both excitatory and 814 
inhibitory cell lineages in risk. bioRxiv. 815 
47. Singh, B., Monteil, A., Bidaud, I., Sugimoto, Y., Suzuki, T., Hamano, S., Oguni, H., Osawa, M., 816 
Alonso, M.E., Delgado-Escueta, A.V., et al. (2007). Mutational analysis of CACNA1G in 817 
idiopathic generalized epilepsy. Mutation in brief #962. Online. Hum Mutat 28, 524-525. 818 
48. Calhoun, J.D., Hawkins, N.A., Zachwieja, N.J., and Kearney, J.A. (2016). Cacna1g is a genetic 819 
modifier of epilepsy caused by mutation of voltage-gated sodium channel Scn2a. Epilepsia 820 
57, e103-107. 821 
49. Lu, B., Zhang, Q., Wang, H., Wang, Y., Nakayama, M., and Ren, D. (2010). Extracellular calcium 822 
controls background current and neuronal excitability via an UNC79-UNC80-NALCN cation 823 
channel complex. Neuron 68, 488-499. 824 
50. Shamseldin, H.E., Faqeih, E., Alasmari, A., Zaki, M.S., Gleeson, J.G., and Alkuraya, F.S. (2016). 825 
Mutations in UNC80, Encoding Part of the UNC79-UNC80-NALCN Channel Complex, Cause 826 
Autosomal-Recessive Severe Infantile Encephalopathy. Am J Hum Genet 98, 210-215. 827 
51. Reinthaler, E.M., Dejanovic, B., Lal, D., Semtner, M., Merkler, Y., Reinhold, A., Pittrich, D.A., 828 
Hotzy, C., Feucht, M., Steinbock, H., et al. (2015). Rare variants in gamma-aminobutyric acid 829 
type A receptor genes in rolandic epilepsy and related syndromes. Ann Neurol 77, 972-986. 830 
52. Cheung, C.C., Yang, C., Berger, T., Zaugg, K., Reilly, P., Elia, A.J., Wakeham, A., You-Ten, A., 831 
Chang, N., Li, L., et al. (2010). Identification of BERP (brain-expressed RING finger protein) 832 
as a p53 target gene that modulates seizure susceptibility through interacting with GABA(A) 833 
receptors. Proc Natl Acad Sci U S A 107, 11883-11888. 834 
53. Wang, J., Lin, Z.J., Liu, L., Xu, H.Q., Shi, Y.W., Yi, Y.H., He, N., and Liao, W.P. (2017). Epilepsy-835 
associated genes. Seizure 44, 11-20. 836 
54. Klassen, T., Davis, C., Goldman, A., Burgess, D., Chen, T., Wheeler, D., McPherson, J., 837 
Bourquin, T., Lewis, L., Villasana, D., et al. (2011). Exome sequencing of ion channel genes 838 
reveals complex profiles confounding personal risk assessment in epilepsy. Cell 145, 1036-839 
1048. 840 
32 
55. Oyrer, J., Maljevic, S., Scheffer, I.E., Berkovic, S.F., Petrou, S., and Reid, C.A. (2018). Ion 841 
Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted 842 
Therapies. Pharmacol Rev 70, 142-173. 843 
56. Epi4K Consortium. (2012). Epi4K: gene discovery in 4,000 genomes. Epilepsia 53, 1457-1467. 844 
57. Shen, D., Hernandez, C.C., Shen, W., Hu, N., Poduri, A., Shiedley, B., Rotenberg, A., Datta, 845 
A.N., Leiz, S., Patzer, S., et al. (2017). De novo GABRG2 mutations associated with epileptic 846 
encephalopathies. Brain 140, 49-67. 847 
58. Hamdan, F.F., Myers, C.T., Cossette, P., Lemay, P., Spiegelman, D., Laporte, A.D., Nassif, C., 848 
Diallo, O., Monlong, J., Cadieux-Dion, M., et al. (2017). High Rate of Recurrent De Novo 849 
Mutations in Developmental and Epileptic Encephalopathies. Am J Hum Genet 101, 664-850 
685. 851 
59. Baulac, S., Huberfeld, G., Gourfinkel-An, I., Mitropoulou, G., Beranger, A., Prud'homme, J.F., 852 
Baulac, M., Brice, A., Bruzzone, R., and LeGuern, E. (2001). First genetic evidence of 853 
GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat 854 
Genet 28, 46-48. 855 
60. Wallace, R.H., Marini, C., Petrou, S., Harkin, L.A., Bowser, D.N., Panchal, R.G., Williams, D.A., 856 
Sutherland, G.R., Mulley, J.C., Scheffer, I.E., et al. (2001). Mutant GABA(A) receptor 857 
gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 28, 49-52. 858 
61. Maljevic, S., Moller, R.S., Reid, C.A., Pérez-Palma, E., Lal, D., May, P., and Lerche, H. (2018). 859 
Spectrum of GABAA receptor variants in epilepsy. Curr Opin Neurol In press. 860 
62. Lal, D., Ruppert, A.K., Trucks, H., Schulz, H., de Kovel, C.G., Kasteleijn-Nolst Trenite, D., 861 
Sonsma, A.C., Koeleman, B.P., Lindhout, D., Weber, Y.G., et al. (2015). Burden analysis of 862 
rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic 863 
generalised epilepsies. PLoS Genet 11, e1005226. 864 
63. Tankard, R.M., Bennett, M.F., Degorski, P., Delatycki, M.B., Lockhart, P.J., and Bahlo, M. 865 
(2018). Detecting Expansions of Tandem Repeats in Cohorts Sequenced with Short-Read 866 
Sequencing Data. Am J Hum Genet 103, 858-873. 867 
  868 
33 
Figure titles and legends 869 
Figure 1. Burden of ultra-rare singletons in LoF-intolerant genes (pLI > 0.995) 870 
This analysis was restricted to 4,042 non-ExAC controls for comparison with epilepsy cases. We 871 
focused on “ultra-rare” variants not observed in the DiscovEHR database. Significance of 872 
association was displayed in FDR-adjusted p-values; odds ratios and 95% CIs were not 873 
multiplicity adjusted. The five functional coding annotations were defined as described in Table 874 
S5. PTV denotes protein-truncating variants; the “damaging missense” and “benign missense” 875 
categories were predicted by PolyPhen-2 and SIFT, while “damaging missense-MPC” was a 876 
group of missense variants with a missense badness score (MPC) ≥ 2. From top to bottom are 877 
the results based on all-epilepsy, DEE, GGE, and NAFE. Epilepsy cases, except for individuals 878 
with NAFE, carried a significant excess of ultra-rare PTV and damaging missense (MPC≥2) 879 
variants compared to controls (FDR < 0.05). PTV burden was higher than missense (MPC≥2) 880 
burden across epilepsy types. 881 
 882 
Figure 2. Burden of ultra-rare singletons annotated as (A) protein-truncating variants or (B) 883 
damaging missense (MPC≥2) variants 884 
“Ultra-rare” variants (URVs) were defined as not observed in the DiscovEHR database. Gene sets 885 
were defined in Table S6, with the number of genes specified in the parenthesis. DEE stands for 886 
individuals with developmental and epileptic encephalopathies, GGE for genetic generalized 887 
epilepsy, NAFE for non-acquired focal epilepsy, and EPI for all epilepsy; NDD-EPI genes are 888 
genes with de novo burden in neurodevelopmental disorders with epilepsy. Star signs indicate 889 
significance after FDR control (“*”: FDR-adjusted p-value < 0.05; “**”: adjusted p-value < 1×10-3; 890 
“***”: adjusted p-value < 1×10-5). PTVs were enriched in candidate epilepsy genes for individuals 891 
with DEE relative to other epilepsy subgroups, but did not show a strong signal in inhibitory, 892 
excitatory receptors or voltage-gated cation channel genes. The burden of damaging missense 893 
(MPC≥2) variants, on the other hand, was stronger across these gene sets compared to PTVs, 894 
34 
especially for GABAA receptor genes and genes involved in GABAergic pathways. Relative to 895 
other epilepsy types, individuals with NAFE consistently showed the least burden of deleterious 896 
URVs. No enrichment was observed from excitatory receptors. 897 
 898 
Figure 3. Gene burden for individuals diagnosed with (A) developmental and epileptic 899 
encephalopathies, (B) genetic generalized epilepsy, or (C) non-acquired focal epilepsy  900 
This analysis focused on ultra-rare (non-DiscovEHR) singleton variants annotated as PTV, 901 
damaging missense (MPC≥2), or in-frame insertion/deletion and used Fisher’s exact test to 902 
identify genes with a differential carrier rate of these ultra-rare deleterious variants in individuals 903 
with epilepsy compared to controls. Exome-wide significance was defined as p-value < 6.8e-07 904 
after Bonferroni correction (Methods). Only SCN1A achieved exome-wide significance for 905 
individuals with DEE.906 
35 
Table 1. Enrichment of ultra-rare protein-truncating or damaging missense (MPC≥2) singletons in epilepsy 
This analysis compared the burden of deleterious pathogenic variants between cases and controls using logistic 
regression, adjusting for sex, the first ten principal components, and overall variant count. FDR correction was based on a 
full list of burden tests in Table S9. Tested epilepsy types included all epilepsies (EPI; N=9,170), developmental and 
epileptic encephalopathies (DEE; N=1,021), genetic generalized epilepsy (GGE; N=3,108), and non-acquired focal 
epilepsy (NAFE; N=3,597). All were compared against 8,436 control samples. Figure 2 shows the enrichment pattern of 
PTVs and MPC≥2 variants across the seven gene sets listed here. 
Gene set  
(# genes) 
Mutation 
(# variants) 
Epilepsy 
type 
Carriers (N) 
OR 95%CI P-value FDR adj. P cases controls 
Known 
epilepsy 
genes 
(43) 
PTV 
(95) 
EPI 67 27 2.37 (1.50-3.74) 2.0e-04 1.2e-03 
DEE 24 27 6.28 (3.48-11.3) 1.0e-09 2.1e-08 
GGE 22 27 2.33 (1.32-4.11) 3.6e-03 1.4e-02 
NAFE 15 27 1.38 (0.72-2.66) 3.4e-01 4.7e-01 
MPC≥2 
(335) 
EPI 235 98 2.21 (1.74-2.81) 1.1e-10 2.8e-09 
DEE 47 98 3.60 (2.50-5.19) 5.0e-12 1.6e-10 
GGE 85 98 2.31 (1.71-3.12) 4.4e-08 6.4e-07 
NAFE 80 98 1.91 (1.41-2.60) 3.3e-05 2.8e-04 
Known DEE 
genes 
(50) 
PTV 
(89) 
EPI 68 21 3.00 (1.82-4.95) 1.8e-05 1.6e-04 
DEE 27 21 9.13 (4.93-16.9) 2.1e-12 7.8e-11 
GGE 25 21 3.57 (1.95-6.54) 3.7e-05 3.0e-04 
NAFE 10 21 1.05 (0.48-2.29) 9.1e-01 9.3e-01 
MPC≥2 
(327) 
EPI 224 101 2.05 (1.61-2.60) 6.5e-09 1.2e-07 
DEE 54 101 4.20 (2.97-5.95) 6.0e-16 1.3e-13 
GGE 85 101 2.22 (1.64-3.00) 2.0e-07 2.6e-06 
NAFE 63 101 1.42 (1.02-1.97) 3.7e-02 8.8e-02 
Neuro-
developmental 
disorders with 
epilepsy 
(33) 
PTV 
(63) 
EPI 49 14 3.22 (1.75-5.90) 1.6e-04 9.9e-04 
DEE 29 14 14.77 (7.4-29.49) 2.3e-14 1.7e-12 
GGE 14 14 2.86 (1.32-6.17) 7.7e-03 2.7e-02 
NAFE 4 14 0.75 (0.24-2.34) 6.2e-01 7.2e-01 
MPC≥2 
(215) 
EPI 149 65 2.11 (1.57-2.84) 9.4e-07 1.1e-05 
DEE 36 65 4.30 (2.81-6.57) 1.8e-11 5.1e-10 
GGE 54 65 2.18 (1.50-3.17) 4.2e-05 3.2e-04 
NAFE 41 65 1.43 (0.96-2.15) 8.0e-02 1.6e-01 
GABA-A 
receptors 
(19) 
PTV 
(17) 
EPI 12 5 1.99 (0.69-5.74) 2.0e-01 3.2e-01 
DEE 1 5 2.25 (0.25-20.2) 4.7e-01 6.0e-01 
GGE 9 5 4.81 (1.57-14.7) 5.9e-03 2.1e-02 
NAFE 1 5 0.37 (0.04-3.27) 3.7e-01 5.0e-01 
MPC≥2 
(62) 
EPI 49 13 3.25 (1.74-6.07) 2.1e-04 1.2e-03 
DEE 7 13 3.65 (1.39-9.54) 8.3e-03 2.8e-02 
GGE 21 13 3.81 (1.86-7.81) 2.5e-04 1.4e-03 
NAFE 15 13 2.67 (1.23-5.77) 1.3e-02 3.9e-02 
GABAergic 
pathway 
(113) 
PTV 
(127) 
EPI 81 44 1.58 (1.10-2.28) 1.4e-02 4.4e-02 
DEE 16 44 2.46 (1.37-4.39) 2.4e-03 1.0e-02 
GGE 28 44 1.60 (0.99-2.57) 5.3e-02 1.1e-01 
NAFE 24 44 1.19 (0.73-1.95) 4.9e-01 6.1e-01 
MPC≥2 
(287) 
EPI 185 101 1.73 (1.35-2.22) 1.6e-05 1.6e-04 
DEE 34 101 2.62 (1.74-3.95) 4.5e-06 4.7e-05 
GGE 68 101 1.86 (1.35-2.56) 1.6e-04 9.9e-04 
NAFE 58 101 1.40 (1.00-1.95) 4.7e-02 1.1e-01 
Excitatory 
receptors 
(34) 
PTV 
(54) 
EPI 22 32 0.66 (0.37-1.15) 1.4e-01 2.5e-01 
DEE 3 32 0.71 (0.21-2.35) 5.7e-01 6.7e-01 
GGE 11 32 1.10 (0.54-2.23) 8.0e-01 8.4e-01 
NAFE 5 32 0.44 (0.17-1.15) 9.5e-02 1.8e-01 
MPC≥2 
(80) 
EPI 47 33 1.28 (0.81-2.02) 2.9e-01 4.3e-01 
DEE 9 33 1.76 (0.81-3.81) 1.5e-01 2.6e-01 
GGE 12 33 0.91 (0.46-1.79) 7.8e-01 8.3e-01 
NAFE 20 33 1.50 (0.84-2.65) 1.7e-01 2.8e-01 
Voltage-gated 
cation 
channels 
(86) 
PTV 
(163) 
EPI 100 63 1.45 (1.05-2.01) 2.5e-02 7.0e-02 
DEE 18 63 2.11 (1.21-3.66) 8.2e-03 2.8e-02 
GGE 31 63 1.38 (0.88-2.16) 1.6e-01 2.7e-01 
NAFE 30 63 1.15 (0.73-1.81) 5.5e-01 6.7e-01 
MPC≥2 
(329) 
EPI 206 121 1.51 (1.20-1.90) 4.7e-04 2.4e-03 
DEE 34 121 2.08 (1.40-3.10) 3.1e-04 1.7e-03 
GGE 73 121 1.52 (1.12-2.07) 6.6e-03 2.3e-02 
NAFE 74 121 1.39 (1.03-1.88) 3.1e-02 8.1e-02 
 
